DUSP1 dephosphorylates and inactivates preferably p38 and JNK and, to a lesser extent, ERK1/255 and may be a viable target for AD therapies given the difficulties associated with the amyloid reduction clinical trials to date56, 57. This evidence concerns the gene MAPK8 and Alzheimer disease.